home All News open_in_new Full Article

PharmaMar avanza con lurbinectedina y recibe una valoración récord

Los avances en el estudio de lurbinectedina para adultos con cáncer de pulmón de célula pequeña coinciden con la valoración récord emitida por los analistas de Needham. Leer


today 4 d. ago attach_file Politics

attach_file Politics
attach_file Politics
attach_file Events
attach_file Transport
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Society
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Events


ID: 2876639033
Add Watch Country

arrow_drop_down